Cargando…

Galectin-3 prospects as a therapeutic agent for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Thomas, Laura, Pasquini, Laura Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2019
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524501/ https://www.ncbi.nlm.nih.gov/pubmed/30964061 http://dx.doi.org/10.4103/1673-5374.253521

Ejemplares similares

Novel Galectin-3 interactions involved in oligodendroglial differentiation make inroads into therapeutic strategies for demyelinating diseases
por: Pasquini, Laura Andrea
Publicado: (2020)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Galectin-3-Mediated Glial Crosstalk Drives Oligodendrocyte Differentiation and (Re)myelination
por: Thomas, Laura, et al.
Publicado: (2018)

Galectin-1 in myelin repair
por: Rinaldi, Mariana, et al.
Publicado: (2016)

Transcriptional upregulation of galectin-3 in multiple sclerosis
por: Mangano, Katia, et al.
Publicado: (2023)

Microglia depletion as a therapeutic strategy: friend or foe in multiple sclerosis models?
por: Wies Mancini, Victoria Sofia Berenice, et al.
Publicado: (2022)

Mesenchymal stem cells require the peripheral immune system for immunomodulating effects in animal models of multiple sclerosis
por: Salinas Tejedor, Laura, et al.
Publicado: (2016)

Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?
por: Macchi, Beatrice, et al.
Publicado: (2016)

Absence of galectin-3 attenuates neuroinflammation improving functional recovery after spinal cord injury
por: Prins, Caio Andrade, et al.
Publicado: (2016)

Drug repurposing for neuroregeneration in multiple sclerosis
por: Küry, Patrick, et al.
Publicado: (2018)

Targeting metabolism to treat multiple sclerosis
por: Bhargava, Pavan
Publicado: (2020)

Multiple sclerosis drug repurposing for neuroregeneration
por: Göttle, Peter, et al.
Publicado: (2023)

Neuroprotective role of galectin-1 in central nervous system pathophysiology
por: Aalinkeel, Ravikumar, et al.
Publicado: (2016)

Past, present and future of preserving and restoring function in the visual system: removing galectin-3 as a promising treatment
por: de Lima, Silmara, et al.
Publicado: (2017)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

Perspectives on neuroreparative therapies for treating multiple sclerosis
por: Xiao, Junhua
Publicado: (2015)

Tremor in Multiple Sclerosis—An Overview and Future Perspectives
por: Makhoul, Karim, et al.
Publicado: (2020)

Immunological role of sulfatide in the pathogenesis of multiple sclerosis
por: Hamatani, Mio, et al.
Publicado: (2023)

Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis
por: Mancini, Andrea, et al.
Publicado: (2019)

Ependymal cells and multiple sclerosis: proposing a relationship
por: Hatrock, Dale, et al.
Publicado: (2019)

Cell-based therapeutic strategies for multiple sclerosis
por: Scolding, Neil J, et al.
Publicado: (2017)

Metabolic checkpoints in neurodegenerative T helper 17 (T(H)17) and neuroregenerative regulatory T (T(reg)) cells as new therapeutic targets for multiple sclerosis
por: Shen, Hongxing, et al.
Publicado: (2019)

Biochemical indicators for neuronal regeneration during intrathecal triamcinolone application in multiple sclerosis
por: Müller, Thomas, et al.
Publicado: (2015)

Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis
por: Pallais, Jean Pierre, et al.
Publicado: (2019)

Trans-synaptic degeneration as a mechanism of neurodegeneration in multiple sclerosis
por: Murphy, Olwen C., et al.
Publicado: (2023)

Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination
por: Azim, Kasum, et al.
Publicado: (2022)

Environmental enrichment as a promising strategy for aiding multiple sclerosis treatment
por: Silva, Berenice Anabel, et al.
Publicado: (2020)

Focusing on caveolin-1 in CNS autoimmune disease: multiple sclerosis
por: Wu, Hao, et al.
Publicado: (2016)

Myelin positron emission tomography (PET) imaging in multiple sclerosis
por: de Paula Faria, Daniele
Publicado: (2020)

The Importance of the Cognitive Aspects of Vocational Rehabilitation for Individuals With Multiple Sclerosis
por: Kennedy, Winston, et al.
Publicado: (2020)

Brain network correlates of epilepsy occurrence in multiple sclerosis and neuroinflammation
por: Ciolac, Dumitru, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis disease modifying therapeutics: a cell biological perspective
por: Tang, Bor Luen
Publicado: (2017)

Synaptic pathology in multiple sclerosis: a role for Nogo-A signaling in astrocytes?
por: Espírito-Santo, Sheila, et al.
Publicado: (2022)

Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19)
por: Li, Sheng-De, et al.
Publicado: (2021)

Pannexin 1-based channels activity as a novel regulator of multiple sclerosis progression
por: Ortiz, Fernando C., et al.
Publicado: (2019)

Neuronal gene transcription modulates demyelination and remyelination in a mouse model of multiple sclerosis
por: Anastasiadou, Sofia, et al.
Publicado: (2015)

Pharmacological interventions targeting nuclear factor-kappa B signaling in multiple sclerosis
por: De Kleijn, Kim M. A., et al.
Publicado: (2021)

Multiple sclerosis: why we should focus on both sides of the (auto) antibody
por: den Dunnen, Jeroen, et al.
Publicado: (2021)

Neuronal and endothelial transglutaminase-2 expression in experimental autoimmune encephalomyelitis and multiple sclerosis
por: Pearse, Damien D., et al.
Publicado: (2021)

Emerging role of neuregulin-1beta1 in pathogenesis and progression of multiple sclerosis
por: Ziaee, Seyyed Mohyeddin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sd4s5cidt7crirkuf8nt8rl1qc